Alerta

NON-VIRAL DELIVERY OF SMALL MOLECULE THERAPEUTICS

Absstract of: AU2023283389A1

The invention relates to nucleic acid nanostructure delivery compositions for non-viral delivery, and methods therefor. More particularly, the invention relates to nucleic acid nanostructure delivery compositions, such as DNA origami compositions, for the delivery, for example, of small molecule therapeutics, and methods therefor.

NON-VIRAL DELIVERY COMPOSITIONS AND SCREENING METHODS

Absstract of: AU2023285047A1

The invention relates to barcoded nucleic acid nanostructure delivery compositions for

CONJUGATE TARGETING CARDIOVASCULAR DISEASE

Absstract of: US2025090683A1

The present invention provides a conjugate comprising: (a) a cardiovascular disease (CVD)-targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or dextran, and (c) a flavonoid. The present invention also provides to a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, optionally (b) an inner shell comprising oligomeric (−)-epigallocatechin gallate (OEGCG), and optionally (c) a CVD-treating molecule encapsulated in the inner shell. The present invention further provides a method for treating a CVD by administering an effective amount of the present nanoparticle composition to a subject. The CVD-targeting ligand targets the heart tissue and delivers active ingredients to heart tissue for treating cardiovascular diseases or conditions.

CATIONIC POLYMERIC NANOCARRIERS INHIBIT CHEMOTHERAPY-INDUCED CANCER METASTASIS AND COGNITIVE IMPAIRMENT

Absstract of: US2025090489A1

PAMAM-based nanocarriers with high loading efficiency of chemotherapeutics and high cfNA binding ability enable sustained delivery of chemotherapeutics while inhibiting systemic inflammation caused by the chemotherapy. This is useful for treating both primary and metastatic tumors with attenuated cognitive impairment.

SUSTAINED ADJUNCT THERAPY TO IMPROVE CHEMOTHERAPY EFFICACY IN GLIOBLASTOMA IN A CEREBROVASCULAR-TUMOR-ON-A-CHIP MODEL

Absstract of: WO2023240213A2

A cerebrovascular unit tumor (CVU-T)-on-a-chip model that models both the blood brain barrier (BBB) and tumor is described. The model provided a physiologically relevant GBM tumor model including a corresponding microenvironment complete with a BBB component that is crucial in dictating drug bioavailability to the tumor. Additionally a novel biodegradable microcapsule for sustained local delivery of a therapeutic such as a connexin hemichannel inhibitor is provided. The therapeutic sensitizes malignant GBM populations to systemic TMZ chemotherapy.

METHOD FOR SYNTHESIZING HYBRID NANOPARTICLES CONTAINING APOLIPOPROTEINS

Absstract of: EP4537818A1

The present invention relates to a method for synthesizing hybrid nanoparticles comprising apolipoproteins. Specifically, the present invention relates to a method for synthesizing hybrid nanoparticles by using a swirling microvortex device, wherein the hybrid nanoparticles may include proteins that include apolipoproteins and have various functionalities. A production method according to the present invention can be used to produce small, uniform, stable nanoparticles having various physiological activities.

NANOPARTICLE FOR USE IN A PROPHYLAXIS OR IN A TREATMENT OF A CALCIFICATION OF BRUCH'S MEMBRANE

Absstract of: EP4537855A1

The present invention provides a nanoparticle comprising a scaffold comprising a biodegradable material, an antibody targeting a component of a Bruch's membrane, and an agent for use in a prophylaxis or in a treatment of a pathological change of Bruch's membrane and/or an adjacent tissue, including a retinal pigment epithelium and a choroid of an eye. Additionally, the present invention provides a pharmaceutical composition comprising said nanoparticle and pharmaceutical acceptable excipients for use in a prophylaxis or in a treatment of a pathological change of Bruch's membrane and/or adjacent tissues, including a retinal pigment epithelium and a choroid of an eye. Preferably said agent is an anti-calcifying agent and said pathological change is a calcification of Bruch's membrane and/or the adjacent tissue, including the retinal pigment epithelium and the choroid of the eye.

MONOLITHIC IMPLANTABLE DEVICE FOR SUSTAINED RELEASE OF AN ANTIBODY

Absstract of: WO2023244526A1

A monolithic implantable device for delivery of an antibody is provided. The implantable device comprises a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents and optionally, one or more excipients. The therapeutic agents contain an antibody and the polymer matrix contains a hydrophobic polymer. Within a time period of 35 days, the device exhibits a cumulative weight-based release ratio of the antibody of from about 20% to about 60%.

HYDROGEL-BASED INJECTABLE NANOCOMPOSITE FOR SURGICAL IMAGING

Absstract of: WO2023238060A1

The present patent application describes an injectable nanocomposite based on a thermo-responsive hydrogel for marking anatomical sites for surgical purposes.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Absstract of: AU2023283348A1

The present disclosure relates to pharmaceutical compositions comprising a lipid nanoparticle (LNP), a therapeutic nucleic acid (TNA) and at least one pharmaceutically acceptable excipient, wherein the LNP comprises at least one lipid, and wherein the LNP is capable of delivering the TNA to a retinal cell. Methods of treating ocular diseases and disorders are also provided.

LIPID MICROBUBBLES FOR THE TARGETED DELIVERY OF ACTIVE AGENTS

Absstract of: WO2023237842A1

The present invention relates to optimised microbubbles, in particular lipid microbubbles, which can be used in the prevention and treatment of diseases or else labelling. The invention relates in particular to a lipid microbubble comprising at least one cationic compound chosen from lipophosphoramidates, histidyl polyethyleneimines, and any mixture thereof. The microbubble preferably also comprises at least one agent chosen from a therapeutic agent, a targeting agent, a labelling agent, and any combination thereof. The invention also relates to a method for producing this microbubble. The present invention also relates to a composition, in particular a pharmaceutical composition, and a kit, comprising at least one of these microbubbles. The present invention also relates to the use of these microbubbles, composition, kit, as a medicament or as a labelling agent.

IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF

Absstract of: AU2023285094A1

Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (

NUCLEOBASE EDITING SYSTEM AND METHOD OF USING SAME FOR MODIFYING NUCLEIC ACID SEQUENCES

Absstract of: WO2023240261A1

The disclosure provides nucleic acid-containing lipid nanoparticle (LNP) compositions and methods relating to the delivery of TnpB nucleobase editing systems comprising TnpB polypeptides, engineered TnpB ncRNAs, and optionally one or more additional accessory functionalities (e.g., a deaminase, reverse transcriptase, recombinase, nuclease, a donor template, or combinations thereof) for use in applications such as precision gene editing.

HER2-GST-SN-38 COMPLEX, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING PROLIFERATIVE DISEASES

Absstract of: EP4537852A1

Provided are a fusion protein including a glutathione-S-transferase and a protein having binding ability to a target cell or a target protein, and a drug complex thereof, and use thereof as a pharmaceutical composition. The fusion protein according to an aspect and the drug complex including the same can sustain a prolonged residence time in vivo, and can be effectively delivered to target cells due to an improved ability to target the target cells, and thus can be effectively used as a targeted therapeutic agent.

负载重组牛干扰素α/γ壳聚糖纳米颗粒的制备方法及其应用

Absstract of: CN119818449A

本发明提供了一种负载重组牛干扰素α/γ壳聚糖纳米颗粒(CS‑TPP‑rBoIFNα/γNPs)的制备方法，制备方法包括：重组牛干扰素α/γ(rBoIFNα/γ)的表达与纯化、rBoIFNα/γ的复性和CS‑TPP‑rBoIFNα/γNPs的制备。还提供了应用，用于制备防治BVDV引起的犊牛腹泻药物。本发明制备的CS‑TPP‑rBoIFNα/γNPs尺寸较小呈均匀分布，在生物体液中可持续释放96h；且CS‑TPP‑rBoIFNα/γNPs包封效果较好，封装效率和负载效率可达76.3％、67.2％；在小鼠体内应用发现CS‑TPP‑rBoIFNα/γNPs能够显著提高rBoIFNα/γ的抗病毒活性。

一种近红外光致半导体聚合物及其水解产物、侧链修饰聚合物、药物递送系统、光刺激响应纳米递送系统及制备方法和应用

Absstract of: CN119823356A

本发明提供了一种近红外光致半导体聚合物及其水解产物、侧链修饰聚合物、药物递送系统、光刺激响应纳米递送系统及制备方法和应用，涉及生物医药技术领域。本发明提供的近红外光致半导体聚合物及其水解产物、侧链修饰聚合物、药物递送系统（OPTC）和光刺激响应纳米递送系统（OPTC‑RNP）在近红外二区成像时，均具有较低的自发背景荧光、较深的组织穿透性和较高的信噪比，近红外二区成像效果优异，可观察到纳米递送系统在肿瘤部位的积累。而且，递送系统中光敏剂能够在近红外光的照射下产生单线态氧，实现肿瘤光动力治疗的同时，可打断OPTC与RNP间连接的化学键而释放核糖核蛋白复合体（RNP），实现光可控的基因治疗。

一种GSH响应型西达本胺异二聚体纳米前药及其制备方法与应用

Absstract of: CN119823140A

本发明涉及医药技术领域，公开了一种GSH响应型西达本胺异二聚体纳米前药及其制备方法与应用，本法制得的GSH响应型西达本胺异二聚体纳米前药负载率高，能高效递送到肿瘤细胞，具有精准释放的能力，并通过协同化疗提高了乳腺癌的治疗效果，采用本法制得的前药能够将CDA和CPT高效递送至肿瘤细胞，实现药物在肿瘤细胞的高效递送和按需释放，提高化疗药物的抗肿瘤效果，以此为化疗药物递送提供了新方向和新思路。

用于PCSK9表达的表观遗传调节的组合物和方法

Absstract of: AU2023265968A1

This application relates to compositions and methods comprising epigenetic editors for epigenetic modification of

一种人源重组单链抗体、纳米颗粒和纳米药物组合物及其应用

Absstract of: CN119823277A

本发明涉及抗体药物技术领域，尤其涉及一种人源重组单链抗体、纳米颗粒和纳米药物组合物及其应用。本发明提供了一种特异性抗PHD2的人源重组单链抗体，所述人源重组单链抗体的氨基酸序列如SEQ ID NO:2所示。本发明得到的人源重组单链抗体较INP更稳定，器官和组织靶向性好。将该人源重组单链抗体与介孔硅纳米颗粒和红细胞膜组合制备成纳米药物组合物，该纳米药物组合物具有更好的治疗疾病的功效。

靶向肿瘤微环境的带负电蜂毒肽纳米胶囊的制备方法

Absstract of: CN119818456A

靶向肿瘤微环境的带负电蜂毒肽纳米胶囊的制备方法，属于靶向肿瘤药物领域。利用蜂毒肽的疏水作用力及氢键作用力，将单体和交联剂富集在蜂毒肽周围，同时加入能够靶向肿瘤细胞表面唾液酸受体的苯硼酸，随后加入引发剂诱导单体和交联剂的聚合，形成交联网络包封蜂毒肽，大幅度提升了药物在体循环后的肿瘤靶向性，降低其对正常组织的毒副作用。大大提升了蜂毒肽在体内的循环时间。

一种负载姜黄素的虫胶脂质体双层混合纳米颗粒、制备方法及其应用

Absstract of: CN119818443A

一种负载姜黄素的虫胶脂质体双层混合纳米颗粒、制备方法及其应用，属于脂质体纳米颗粒制备技术领域。提供了一种负载姜黄素的虫胶脂质体双层混合纳米颗粒，包含负载有姜黄素的虫胶纳米粒子，并在虫胶纳米粒子的表面包被有脂质体双层结构。还提供了上述负载姜黄素的虫胶脂质体双层混合纳米颗粒的制备方法：将姜黄素和虫胶溶于乙醇中，制备有机相共溶液，制备姜黄素@虫胶纳米颗粒。将磷脂和胆固醇溶于乙醇中，制备有机相共融液。制备不同浓度的姜黄素@虫胶浓度的分散液。制备负载姜黄素的虫胶脂质体双层混合纳米颗粒。本发明纳米颗粒大小均一，具有良好的生物相容性和生物降解性，无毒、无刺激，无需加入表面活性剂，进一步降低了毒性。

一种呼吸道合胞病毒mRNA疫苗及其制备方法和应用

Absstract of: CN119818668A

本发明公开了一种呼吸道合胞病毒mRNA疫苗及其制备方法和应用，通过对preF抗原序列进行密码子优化，选择合适的启动子、5’‑UTR、3’‑UTR和3’‑端PolyA组合成完整的编码RSV病毒preF的序列，再经合成、反转录、纯化得到mRNA，并在5条兼顾表达水平和稳定性的核酸序列中筛选获得2条细胞水平表达preF蛋白的稳定性高以及与中和抗体的结合能力强的序列；并改进了脂质纳米颗粒的组分，增强目的抗原在体内的表达，使得制备得到的mRNA疫苗，免疫小鼠后产生强烈且持久的免疫效果且对病毒的保护力更强。

用于脂质纳米颗粒制剂的脂质

Absstract of: AU2023338228A1

Compounds are provided having the following Structure (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R

一种蛋白基生物材料及其制备方法与应用

Absstract of: CN119823289A

本发明实施例公开了一种蛋白基生物材料及其制备方法与应用。所述方法包括：构建含有编码类胶原蛋白基因和刺猬蛋白基因的重组载体，经表达，纯化后，得到重组蛋白；将重组蛋白与胆固醇在TBS缓冲液存在下进行反应，得到所述蛋白基生物材料。本发明提供的具有功能性的胆固醇修饰多肽的混合生物材料，并在纳米尺度上表现出可编程的自组装，在治疗糖尿病等疾病、组织修复、组织工程支架和治疗、药物递送等生物医学原材料，具有较大的市场价值潜力，为未来生物医用材料的发展做出贡献。

高效控释NO的蝴蝶形肽类树状大分子及其合成方法

Nº publicación: CN119823214A 15/04/2025

Applicant:

福建医科大学